Skip to main content
The Website Services team at NHS England are testing early designs to understand how you find information. Your views will help us check our ideas work. Sign up to take part in our user research.

Publication, Part of

National Diabetes Audit, 2019-20 , Type 1 Diabetes

Audit, Survey, Other reports and statistics

Publication Date:
12 Aug 2021
Geographic Coverage:
England, Wales
Geographical Granularity:
NHS Trusts, GP practices, Integrated Care Boards, Regions
Date Range:
01 Jan 2019 to 31 Mar 2020
Page contents

Summary

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards. This is the Type 1 Diabetes report. It details the findings and recommendations relating to diabetes care process completion, treatment target achievement and structured education for people with type 1 diabetes. The 2019-20 audit covers the period 01 January 2019 to 31 March 2020.

This is the first NDA report dedicated to people with type 1 diabetes. A new diagnosis validation process, which considers medication as well as recorded diagnosis, has been introduced to try to ensure that only people with true type 1 diabetes are included (see appendix). Results are to be taken in the context of low data submission from specialist services, possibly hampered due to COVID-19.

Highlights

•The number of people with type 1 diabetes confirmed at an adult specialist service was low (78,585, 35.9 per cent of the total number of people with type 1 diabetes, 218,670). From 135 acute hospital trusts, some with multiple hospitals: 38 submitted the core and insulin pump datasets; 5 submitted only the pump dataset; 55 submitted only the core dataset. This is a much lower level of participation than for the National Paediatric Diabetes Audit*.
•The national median rate for HbA1c ≤ 58mmol/mol (7.5%) is 27.6 per cent, with a variation between 18.4 per cent and 40.9 per cent amongst Clinical Commissioning Groups (CCGs)/Local Health Boards (LHBs).
•Individuals with type 1 diabetes are more likely to have recommended HbA1c levels if they are on insulin pump treatment. Overall, around 10 per cent of people with type 1 diabetes use insulin pumps, but this varies appreciably by CCG/LHB locality from 3.2 per cent to 24.6 per cent. More than 70,000 people with type 1 diabetes meet one of the NICE criteria for offering insulin pump treatment as they are on basal-bolus treatment and have an HbA1c ≥ 69 (8.5%).
•Individuals with type 1 diabetes are more likely to have high HbA1c levels (>86mmol/mol) if they are young, female, of minority ethnicity, or live in an area of high deprivation.

Last edited: 10 August 2021 4:55 pm